Archives
-
DMG-PEG2000-NH2 for LNP Conjugation Workflows
2026-09-15
DMG-PEG2000-NH2 combines a lipid-compatible DMG segment, PEG2000 spacer, and reactive primary amine for controlled biomolecule attachment. This article presents practical coupling, purification, LNP formulation, siRNA encapsulation, and troubleshooting workflows while separating product-enabled applications from evidence generated in a distinct sulfonamide study.
-
Rimonabant (SR141716) Workflow for CB1 Research
2026-09-15
Build cleaner CB1 experiments with Rimonabant (SR141716), from appetite and obesity research to inflammation and neurobiology assays. A practical workflow separates CB1-dependent effects from A2A-receptor mechanisms highlighted in recent terpene pain research, while addressing formulation, cytotoxicity, and behavioral confounds.
-
Axitinib (AG 013736) Cancer Assay Workflows
2026-09-14
Build more informative angiogenesis and cancer biology experiments with Axitinib (AG 013736), from VEGF-stimulated endothelial assays to paired viability and cell-death measurements. This workflow emphasizes dosing discipline, signaling confirmation, and practical troubleshooting so apparent drug response is not confused with simple growth arrest.
-
TRIB3, Ferroptosis, and Sunitinib Sensitivity in ccRCC
2026-09-14
The reference study identifies TRIB3 as a potential regulator of sunitinib resistance in clear cell renal cell carcinoma, linking TRIB3 depletion to ferroptosis through the SLC7A11/GPX4 antioxidant pathway. Its combination of bioinformatics, siRNA perturbation, drug-response testing, and protein analysis provides a useful framework for mechanistic studies of targeted-therapy resistance.
-
LY-411575 Workflow for Gamma-Secretase Research
2026-09-13
Build cleaner APP and Notch experiments with LY-411575, a sub-nanomolar gamma-secretase inhibitor suited to parallel molecular and functional readouts. This guide combines pathway-specific controls, practical dosing workflows, and troubleshooting strategies for Alzheimer's disease research and cancer research.
-
GSK-923295: A Mechanistic Guide to CENP-E
2026-09-12
GSK-923295 is a potent CENP-E inhibitor for dissecting mitotic kinesin function, chromosome alignment, and tumor-cell vulnerability. This guide adds a practical assay framework for distinguishing motor inhibition from centromere-architecture defects revealed by acute CTCF degradation.
-
Arachidonic Acid: From Lipid Signal to Immune Strategy
2026-09-11
Arachidonic Acid is more than a membrane lipid or inflammation model. Its position at the intersection of eicosanoid biosynthesis, immune-cell signaling, and vaccine response creates a strategic opportunity for translational researchers—provided substrate handling, pathway attribution, and evidence maturity are treated as core design variables.
-
Sulfaphenazole-Derived Sulfonamides Against TB
2026-09-11
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP2C9 inhibition, a liability associated with potential drug–drug interactions. Compound 10d emerged as a useful lead with a reported MIC of 5.69 μg/mL and CYP2C9 IC50 greater than 10 μM, although the evidence remains primarily in vitro.
-
XAV-939 Workflows for Wnt Pathway Research
2026-09-10
Use XAV-939, also known as NVP-XAV939, to connect tankyrase inhibition with measurable changes in β-catenin signaling, cell fate, endothelial protection, fibrosis, and osteogenesis. This practical workflow emphasizes dosing controls, pathway-specific readouts, and troubleshooting across cancer research, fibrotic disease research, and bone formation disorder studies.
-
Fludarabine DNA Synthesis Inhibitor Workflows
2026-09-10
Build reproducible Fludarabine workflows for cell-cycle arrest, apoptosis, leukemia research, and multiple myeloma research. The same compound can also support carefully controlled studies of lymphodepletion and antigen presentation, provided regimen-level immunotherapy findings are not overinterpreted as effects of Fludarabine alone.
-
2-Deoxy-D-glucose: Practical Glycolysis Workflows
2026-09-09
2-Deoxy-D-glucose (2-DG) provides a practical way to perturb glucose dependence, ATP production, and metabolic stress across cancer, osteoblast, and antiviral models. This guide connects concentration planning and troubleshooting with a recent Wnt–glycolysis study, helping researchers distinguish pathway-specific biology from nonspecific cytotoxicity.
-
Hexamethonium Bromide in Autonomic Research
2026-09-09
Hexamethonium Bromide provides a mechanistic way to interrogate autonomic ganglionic transmission rather than merely describe blood-pressure phenotypes. This article explains how to interpret ganglionic blockade in sex-specific hypertension research and how B1592 can support rigorous neuronal signaling studies.
-
Computational Modeling of Rodent Depression Tests
2026-09-08
A 2025 Cell Reports Methods study combines automated tracking with computational modeling to examine the cognitive processes expressed during forced swim and tail suspension tests. Its findings show that the assays share some reinforcement-learning features but are not interchangeable, while learning-related influences dominate early behavior and consequence sensitivity becomes more important later.
-
TTP, m6A, and Fibrosis in Schistosomiasis
2026-09-08
The reference study identifies tristetraprolin as an antifibrotic regulator that enhances WTAP-dependent m6A modification of TGF-β1 mRNA, reducing transcript stability and hepatic stellate cell activation. Its combination of disease modeling, molecular perturbation, MeRIP-seq, transcriptomics, and proteomics provides a mechanistic framework for studying epitranscriptomic control of schistosomiasis-associated liver fibrosis.
-
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-09-07
Build a sensitive, flexible western blot workflow for low-abundance targets using HRP-based detection on nitrocellulose or PVDF. This practical guide connects substrate handling, exposure strategy, assay optimization, and pathway-focused validation to the SVP3 hypolipidemia study.